Dr. Gulley on Checkpoint Inhibitors in Bladder Cancer

James L. Gulley, MD, PhD, Chief, Genitourinary Malignancies Branch, Senior Investigator, Head, Immunotherapy Section, Director, Medical Oncology Service, CCR Office of the Clinical Director, National Cancer Institute, discusses checkpoint inhibitors in bladder cancer.

Checkpoint inhibitors are currently being investigated in a wide range of clinical trials in bladder cancer. Data has suggested significant activity of atezolizumab, pembrolizumab, avelumab in patients with metastatic bladder cancer.

Now that activity is being seen, further investigation is needed to determine if these agents should be used as single agents or in earlier settings, says Gulley.